Review article

Challenges in the management of glaucoma in developing countries

Nadeem Hafeez Butt*, Muhammad Hammad Ayub, Muhammad Hassaan Ali

Department of Ophthalmology, Allama Iqbal Medical College/Jinnah Hospital, Lahore, Pakistan

1. Introduction

Globally, glaucoma is the most common optic neuropathy, the second common cause of blindness, and the most common cause of preventable visual disability.1 Glaucoma includes a spectrum of progressive optic neuropathies characterized by pathological degeneration of nonmyelinated retinal ganglion cells, with structural damage at the level of optic nerve head. The common pathway in the pathogenesis of glaucoma is triggering of accelerated apoptosis of the retinal ganglion cells.2 As a consequence of neuronal death within the central visual pathway, clinical signs of glaucoma start appearing. These signs include retinal nerve fiber layer defects, thinning of the neuroretinal rim, and excavation of the optic nerve head, commonly called cupping of the optic disc. These structural changes lead to functional defects in the form of irreversible visual field loss.3

In the currently published literature on glaucoma, intraocular pressure (IOP) is not considered to be a part of the definition of glaucoma; however, it is the most easily modifiable risk factor to decrease the risk of disease onset and progression.4 IOP reduction by medical, laser, and surgical treatments remain the only clinically proven treatment of glaucoma.5 However, Collaborative Normal Tension Glaucoma study has exemplified that lowering of IOP alone is not entirely effective for all patients of glaucoma.6 In some patients, sufficient IOP reduction to slow down or arrest the disease process may be either difficult or full of adverse effects of treatment.

2. Magnitude and burden of the disease

According to the World Health Organization estimates of 2002, the number of people blinded by glaucoma was 4.4 million (12.3% of the blind people worldwide). The majority of those with glaucoma remain undetected, and estimates of people afflicted by glaucoma and related blindness are made on the basis of data from epidemiological studies. From these studies, it has been understood that glaucoma affects all populations, but there is a disparity in distribution. This disparity is either because of a higher prevalence and racial predilection or because of a large population in these regions resulting in a larger absolute number of persons with glaucoma.7

The type of glaucoma also varies from region to region. Primary open-angle glaucoma (POAG) is the predominant glaucoma in...
North America, Europe, and European-derived populations of Australia. The highest prevalence of glaucoma in these regions is observed in the African and Caribbean origin population in the USA and the Caribbean. A study by Quigley and colleagues demonstrated that nearly half of the population with glaucoma resides in Asia, which includes the three most populous countries—China, India, and Pakistan. Prevalence surveys in Mongolia, Singapore, China, and India have observed the prevalence of primary angle closure glaucoma to be equal to that of POAG, and is similar to that of Caucasians.2

The prevalence of combined glaucoma (primary and secondary) in Tanzanian and South African studies was reported to be 5%. The predominant type of glaucoma is POAG.

The total global estimate of POAG and PACG for the year 2020 was considered to be 60.5 million and 79.6 million respectively in year 2010.

3. Challenges

3.1. Early detection and diagnosis

The anatomical and functional changes from glaucoma are largely irreversible; therefore, early disease detection remains an important strategy to prevent visual impairment. This has been achieved by assessing optic nerve structure using imaging devices and optic nerve function through perimetry. Imaging and perimetry techniques have improved considerably, and new strategies are emerging to complement these established techniques.2 These include retinal nerve fiber layer analysis and detection of retinal ganglion cells apoptosis in vivo. Spectral-domain optical coherence tomography in glaucoma offers the opportunity of objectively measuring the retinal nerve fiber layer and its associated changes with time. Although it can achieve a resolution of 3–6 μm, it is dependent on establishing structural and functional relationships. The ability to detect pre-perimetry glaucoma has been a goal in clinical management of glaucoma for several decades.11 A technique termed as “detection of apoptotic retinal cells” has been developed, which utilizes nonradioactive fluorescent-labeled annexin V and high-resolution imaging to enable real-time detection of apoptosis in retinal ganglion cells. The technology has been demonstrated well in animal models but has to undergo Phase I clinical trials for its safety assessment.12

3.2. Setting of IOP targets

IOP has been identified as the only modifiable risk factor, and lowering of IOP to prevent progression of glaucoma is now the backbone of glaucoma management. A growing body of evidence shows that not only the mean IOP reduction is important, but also control of fluctuation of IOP plays a major role in the preservation of vision and visual fields.13

European Glaucoma Society has defined the target IOP as the mean IOP obtained with treatment that prevents further glaucomatous damage. Formulation of the target IOP is one of the most important steps in treatment. It is generally assumed that aiming to achieve at least a 30% reduction from the initial pressure at which damage occurred is a useful arbitrary way to achieve the initial target IOP. The target IOP is the IOP range at which the clinician decides that progressive disease is unlikely to affect the patient’s quality of life (QOL). Besides, the target IOP can be explained as the upper limit of a stable range of measured IOPs deemed likely to retard further optic nerve damage.14

The target IOP is determined on the basis of the following factors: amount of glaucoma damage; the IOP at which the damage has occurred; life expectancy of the patient; status of the fellow eye; and family history of glaucoma.

It is recommended that the target IOP be recorded so that it is accessible on subsequent patient visits. The target IOP is not a static value; rather, it requires periodic re-evaluations. When setting the target IOP, each eye is staged into one of four severity groups: suspect, early, moderate, or advanced glaucoma based on the following factors: assessment of the optic nerve and visual fields; patient factors especially IOP; age; life expectancy; quality of life; risk factors for progression; and patient’s own input (Table 1).12

However, it should be remembered that there is a fine line between setting an appropriate goal to prevent optic nerve damage and being overly aggressive in IOP lowering.

3.3. More target IOP recommendations

Stage each eye of the patient as normal, suspect, early, moderate, or advanced glaucoma based on optic nerve and (or) visual field examination.

Set the upper limit of the initial target IOP range for each eye at the first visit and then re-evaluate at each visit based on stability/change in structure and function of the optic nerve (i.e., Optic nerve head (ONH) examination with or without additional imaging information as well as visual field data). The suggested upper limit of the target IOP as described by various studies is given in Table 2.15

IOP telemetry is done through a device called telemetric strain gauge contact lens (Sensimed Triggerfish).16 The device measures the changes in corneal curvature with fluctuation in IOP. Variation of 1 mmHg produces a change of central corneal curvature radius of ~3 μm. A reading of 30 second duration is taken every 5 minutes over a 24-hour period.17

4. Choice of treatment

The choice of treatment is multifactorial and depends on the level of IOP, fluctuation of IOP, stage of disease, pace of progression, current treatment, and past treatments. Medical, laser, and surgical treatments are available in almost all parts of the world, with variations and preferences according to local populations. All the currently available treatments are targeted toward IOP control, which is a risk factor for glaucoma but not necessarily the sole cause of disease progression. Recent exciting developments in glaucoma management address these concerns. These include the development of a new class of IOP-lowering medications known as

| Severity group | Characteristics |
|----------------|-----------------|
| Suspect        | 1 or 2 of the following: IOP >21 mmHg; suspicious disc or C/D asymmetry of >0.2; suspicious 24-2 (or similar) VF defect |
| Early          | Early glaucomatous disc features (e.g., C/D >0.65) & (or) mild VF defect not within 10° of fixation (e.g., MD better than –6 dB on HVF 24-2) |
| Moderate       | Moderate glaucomatous disc features (e.g., vertical C/D 0.7–0.85) & (or) moderate VF defect not within 10° of fixation (e.g., MD from –6 dB to –12 dB on HVF 24-2) |
| Advanced       | Advanced glaucomatous disc features (e.g., C/D >0.9) & (or) VF defect within 10° of fixation (e.g., MD worse than –12 dB on HVF 24-2) |

C/D – cup-to-disc ratio; HVF – Humphrey visual fields; MD – mean deviation; VF – visual field.
Rho-kinase inhibitors, newer and safer techniques for surgically reducing IOP, and the development of non-IOP-dependent therapies such as neuroprotection. Brimonidine and memantine are the prototype medicines that are in clinical use for neuroprotection. The conventional treatment includes groups of drugs such as beta-blockers, prostaglandin analogues, carbonic anhydrate inhibitors, alpha agonists, and parasympathomimetics.

For longer than the past two decades, the paradigm of the drug of first choice has shifted from beta-blockers to prostaglandin analogues. In case of poor IOP control, the add-on therapy is in the form of fixed combinations of two drugs available in almost all parts of the world.

For patients who cannot tolerate medications or are inadequately controlled with medications, laser treatment continues to be an excellent alternative in the developed parts of the world. The laser may also be used as a primary treatment option in case of pre-existing ocular surface disorder. The most common laser treatment for glaucoma is argon laser trabeculoplasty. A new type of laser, called micropulse laser trabeculoplasty, is currently being studied as yet another option for effectively increasing drainage of eye fluid to lower IOP.

Trabeculectomy with or without adjuncts is still considered the procedure of first choice, especially in the developing world. Modified procedures with variable outcomes include viscosocanostomy, nonpenetrating glaucoma surgery, shunts or tube implants, collagen matrix implants, and high-frequency deep sclerectomy.

All these procedures demand specialized training, expertise, and equipment, which vary from region to region.

### 5. Quality of life and quality of sight

Patients suffering from glaucoma can lose QOL for several reasons: the diagnosis itself, functional loss, inconvenience of treatment, side effects of treatment, and cost of treatment. Glaucoma therapy, whether medical or surgical, can directly influence a patient’s QOL. Health-related QOL is an important outcome in glaucoma, and it can be measured using either generic or vision-specific instruments. Generic instruments include the Medical Outcomes Study Short Form 36, sickness impact profile, Euro QOL Health Questionnaire, and utility values among others. The most commonly used vision-specific instrument is the 25-question version of the National Eye Institute Visual Functioning Questionnaire.

Ocular surface disease is a group of disorders that affect various components of the ocular surface tissues. It has become increasingly common with growing age.

Glaucoma primarily affects patients in the 5th–7th decades of their lives; therefore, ocular surface disease poses an increased risk to them, and more than 50% of patients with glaucoma and receiving antiglaucoma medications have ocular surface disease in at least one eye. This is of serious concern because ocular surface disease results in dysfunction of the ocular tear film with wide-ranging symptoms and signs, including discomfort, grittiness, burning, foreign body sensation, dryness, ulceration, and even scarring. All these symptoms and signs negatively affect the QOL of these patients.

Topical antiglaucoma medications have been associated with ocular surface disease because they are instilled as drops into the tear film, where they interact with ocular surface tissues.

This interaction can involve the active agents themselves or preservatives used to keep the bottles sterile and to stabilize the active agents in solutions. Benzalkonium chloride is a detergent-like preservative common to most antiglaucoma medications. Studies have shown that benzalkonium chloride can damage corneal and conjunctival epithelial cells and decrease conjunctival goblet cell density, thereby reducing tear film stability and promoting dry eye.

Since antiglaucoma treatment is long term and often involves multiple medical therapies, the potential for adverse interactions increases with time. The negative effect of dry eye on QOL cannot be overestimated. The reasons for nonadherence to treatment regimens are multifactorial, but they at least partly depend on discomfort of the eyes.

### 6. Compliance, adherence, and persistence

Traditionally, compliance has been defined as the extent to which patients’ behavior corresponds to physician’s recommendations. However, in recent literature, the term compliance has been replaced by adherence and persistence. Adherence is the measure of the degree to which a patient follows prescribed instructions during a defined time period, and persistence, by contrast, is a criterion that evaluates the time until the patient first discontinues the use of medications.

Patients routinely overestimate their adherence to eye drops. In fact, 95% of patients claimed in one study (Glaucoma Adherence and Persistence Study) that they never missed taking drops, despite clear evidence that adherence of these patients was dramatically lower.

Persistence with glaucoma medications has been found to be low in several studies, varying from 20% to 64%. Glaucoma suspects beginning latanoprost or a beta-blocker drop had persistency rates of 39% and 25%, respectively, at 1 year.

Clinical implications of nonadherence and nonpersistence are serious. Determining, maintaining, and adjusting a target pressure range for patients are important in glaucoma care. A patient who resumes medication shortly before an office visit after a gap in therapy may appear to have an optimal pressure, yet visual field progression may have occurred. In this situation, it becomes impossible to decide whether the pressure goal needs to be further lowered or whether the pressure goal is appropriate but the patient is progressing because of nonadherence to therapy, as the IOP is above the goal for the period of nonadherence.

Medications work only for patients who take them. Glaucoma patients may have variable clinical courses of the disease itself, which is further confounded by improper or irregular medication use. Greater awareness among physicians of the widespread nature of nonadherence is a very important component of patient care.

There are certain ways by which patients’ compliance can be improved. The most important of them appears to be good...
counseling of patients and their families regarding the nature of the disease, and an explanation of the role and importance of the medications advised. It is equally important to simplify the prescribed regimen by giving fixed combinations wherever possible, to limit the number of eye drops being used by the patient. If a patient admits that the cause of poor compliance is the cost of the medicine, then the treating physician should consider prescribing equally efficacious drugs with a lower cost or consider surgical or laser treatment for the patient.

References

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267.
2. Quigley HA, Nickels RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36:774–786.
3. Yuwel YH, Zhang Q, Weinreb RN, Kaufman PL, Gupta N. Atrophy of relay neurons in magno- and parvocellular layers in the lateral geniculate nucleus in experimental glaucoma. Invest Ophthalmol Vis Sci. 2001;42:3216–3222.
4. AGIS Investigators The. The Advanced Glaucoma Intervention Study (AGIS): The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2002;130:429–440.
5. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48–56.
6. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487–497.
7. Vijaya L, George R, Paul P, Baskaran M, Arvind H, Raju P, et al. Prevalence of open-angle glaucoma in a rural south Indian population. Invest Ophthalmol Vis Sci. 2005;46(12):4641–4647.
8. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996 May;80(5):389–393.
9. Jacob A, Thomas R, Koshi SP, Braganza A, Mulvihil J. Prevalence of primary glaucoma in an urban South Indian population. Indian J Ophthalmol. 1998;46:81–86.
10. Sung KR, Kim JS, Wollstein G. Imaging of the retinal nerve fibre layer with spectral domain optical coherence tomography for glaucoma diagnosis. Br J Ophthalmol. 2011;95:909–914.
11. Vizzere G, Weireh RN, Gonzalez-Garcia AO, et al. Agreement between spectral domain and time domain OCT for measuring RNFL thickness. Br J Ophthalmol. 2009;93:775–781.
12. Guo L, Cordeiro MF. Assessment of neuroprotection in the retina with DARc. Prog Brain Res. 2008;173:437–450.
13. Spaeth GL, Bernstein P, Caprioli J, Schiffman RM. Control of intracocular pressure and fluctuation with fixed combination brimonidine or timolol mono therapy. Am J Ophthalmol. 2011;151:93–99.
14. American Academy of Ophthalmology. Primary Open-Angle Glaucoma. Preferred Practice Pattern. San Francisco, CA: American Academy of Ophthalmology; 2005.
15. Canadian Ophthalmological Society. Evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol. 2009;44:Suppl. 1:57–593.
16. Mansouri K, Weireh R. Continuous 24-hour intraocular pressure monitoring for glaucoma—time for a paradigm change. Swiss Med Wkly. 2012;142:w13545. http://dx.doi.org/10.4414/smw.2012.13545.
17. Pajic B, Pajic-Eggspuchler B, Haefliger L. Continuous IOP fluctuation recording in normal tension glaucoma patients. Curr Eye Res. 2011;36:1129–1138.
18. Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008;20:242–248.
19. Brown GC. Vision and quality of life. Trans Am Ophthalmol Soc. 1999;92:474–511.
20. Jampel HD. Glaucoma patients’ assessment of their visual function and quality of life. Trans Am Ophthalmol Soc. 2001;99:301–317.
21. Mors SE, Klein R, Klein BE. Prevalence of and risk factor for dry eye Syndrome. Arch Ophthalmol. 2000;118:1264–1268.
22. Leung EW, Mediros FA, Weingreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–355.
23. Nocker RJ, Hsuvaors LA, Arowuradd R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490–496.
24. Kabook MY, Noeker RJ. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther. 2008;25:743–751.
25. Al Naumi D, Salam T, Raj S. Side effects of eye drops V compliance: patients’ perspective. Program and abstracts of the World Glaucoma Congress 2009, July 8–11. 2009. Boston, MA. Abstract P419.
26. Schwartz GF. Compliance and persistency in glaucoma follow up treatment. Curr Opin Ophthalmol. 2005;16:114–121.
27. Friedman DS, Hahn SR, Gelb L, et al. Doctor—patient communication and health related beliefs: results from the Glaucoma Adherence and Persistency Study (GAPS). Ophthalmology. 2008;115:1320–1327.
28. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48:5052–5057.
29. Quigley HA, Friedman DS, Hahn SR. Evaluation of practice pattern for the care of open angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. Ophthalmology. 2007 Sep;114(9):1599–1606.
30. Spooner B, Bullano MF, Ikeda L, et al. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care. 2002;8:5262–5270.
31. Dasgupta S, Dates V, Bookhart BK, et al. Population based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care. 2002;8:S 255–S 261.
32. Schwartz GF, Reardon G, Mozafari E. Persistency with Latanoprost or timolol in primary open angle glaucoma suspects. Am J Ophthalmol. 2004;137:5 13–5 16.
33. Graver JA. Effect of partial compliance on cardio vascular medication effectiveness. Heart. 2002;88:203–206.
34. Friedman DS, Nordstrom B, Mozafari E, Quigley HA. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology. 2005;112:1500–1504.